The effect of AA-signalling agonists and antagonists on the viability of SH-SY5Y neuroblastoma cells treated with ATRA (dose-response) in combination with fixed doses of the 5-LO inhibitors celecoxib or MK886.

<p>SH-SY5Y cells were pre-treated with 0.1 µM 5-oxo-ETE, 0.1 µM LTA4 or 0.1 µM L165-041 2 h prior to treatment with 22 µM celecoxib and an ATRA dose response, or 1 µM MK886 and an ATRA dose response. Viability was measured 24 h after treatment using XTT assays. The IC₅₀ values are for the ATRA dose-response with fixed doses of the 5-LO inhibitors celecoxib or MK886 and in the presence of agonist/antagonist or control vehicle, and the lower asymptote reflects the viability of cells at the highest concentrations of ATRA in the dose-response curve. For viability experiments, there were three technical replicates for each of three dose-response experiments. Results are mean %±SEM.